Meeder Asset Management Inc Amicus Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$11.43 - $14.24 $4,274 - $5,325	374 New	374 $4,000
Q4 2021 Feb 11, 2022	SELL	$9.82 - $12.44 $13,748 - $17,416	-1,400 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$8.74 - $11.84 $11,632 - $15,759	1,331 Added 1928.99%	1,400 $13,000
Q2 2021 Aug 09, 2021	SELL	$8.71 - $10.72 $339 - $418	-39 Reduced 36.11%	69 $1,000
Q1 2021 Apr 28, 2021	BUY	$9.2 - $23.86 $993 - $2,576	108 New	108 $1,000
Q4 2020 Feb 09, 2021	SELL	$13.47 - $24.89 $78,651 - $145,332	-5,839 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$12.89 - $15.89 $98,556 - $121,494	-7,646 Reduced 56.7%	5,839 $83,000
Q2 2020 Aug 11, 2020	BUY	$8.86 - $15.69 $103,015 - $182,427	11,627 Added 625.78%	13,485 $202,000
Q1 2020 May 15, 2020	BUY	$6.63 - $11.16 $12,318 - $20,735	1,858 New	1,858 $17,000
Q3 2019 Oct 17, 2019	SELL	$8.02 - $13.25 $46,933 - $77,539	-5,852 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$10.96 - $14.4 $64,137 - $84,268	5,852 New	5,852 $73,000
Q4 2017 Feb 02, 2018	SELL	$12.51 - $16.24 $3,390 - $4,401	-271 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$11.74 - $15.78 $3,181 - $4,276	271	271 $4,000

312

311M

467K

515K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.55B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.